Introduction
Human hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver which represents the fifth most common cancer and second leading cause of cancer-related mortality worldwide (1, 2). Prognosis of HCC is poor, and curative treatments (resection, liver transplantation, local ablation) can only be applied to a limited number of patients as the diagnosis is often made at an advanced stage of the disease (3). Sorafenib (Nexavar), is the first and only FDA-approved drug that is clinically approved for patients with advanced HCC (4) (5) (6) . Sorafenib, is a multi-kinase inhibitor of more than dozen kinases at nanomolar potency, including serine/threonine kinases c-Raf and B-Raf, the receptor tyrosine kinases VEGFR2, VEGFR3, platelet-derived growth factor receptor (PDGFR), FLT3, Ret and c-kit (7) . However, the increased survival benefit related to Sorafenib treatment is limited to about 3 months, emphasizing the need for the development of new treatment strategies (8) .
Recent publications indicate that HCC cell activation by different factors is known to increase both Ras/Raf/MAPK and PI3K/AKT/mTOR signaling (9) . Sorafenib, the only drug for treatment of patients with advanced HCC inhibits Ras/Raf/MAPK pathway (8) but does not directly inhibit the PI3K/AKT/mTOR pathway which also plays an important role in HCC proliferation. PI3K pathway is known to be activated in 30-50% of HCC cases (10) . In HCC, somatic mutation of PIK3CA, enhancement of Akt and phosphorylated ribosomal protein S6 and decrease of PTEN expression have been reported (11) (12) (13) (14) . These observations suggest that combined targeting of PI3K/AKT/mTOR and Ras/Raf/MAPK pathway might provide benefit in the treatment of HCC. In this regard, other labs have used PI-3K/mTOR inhibitor PI-103 and PKI-587 in combination with Sorafenib and found that these drugs can synergistically block Ras/Raf/ MAPK and PI3K/mTOR pathways (15, 16) . However these drugs are not slated to enter clinical trials for treatment of cancer patients (17) (18) (19) , hence there is an urgent need to find a PI-3K drug which is in clinical trials and can be used to treat HCC patients. SF1126, a pan-PI-3K inhibitor, has shown anti-tumor and anti-angiogenic activity in a number of xenograft models (20) (21) (22) (23) (24) (25) . Furthermore, this drug has recently been shown to be safe (no dose limiting toxicity or hepatotoxicity) and have considerable efficacy in B cell malignancies and a variety of solid tumors in a Phase I clinical trial (26) . SF1126 is an RGDS-conjugated LY294002 prodrug, which is designed to exhibit increased solubility and bind to specific integrins within the tumor compartment, resulting in enhanced delivery of the active compound to the tumor vasculature and tumor (27) . Recent study has demonstrated that LY294002 the active moiety of SF1126, has been cocrystallized in the active site of BRD4 and inhibits BET bromodomain binding to acetylated lysine binding sites within chromatin (28) . The bromodomain and extraterminal domain (BET) proteins recently emerged as important therapeutic targets in several types of hematopoietic cancers (29) (30) (31) (32) .
Bromodomains are protein motifs that primarily bind to acetylated lysine residues, including those on histone tails (33) . The BET family proteins (BRD2, BRD3, BRD4, BRDT) contain 2 amino-terminal bromodomains and have recently been recognized in the literature as a therapeutic strategy to target c-Myc (32). c-Myc transcription factor is frequently upregulated in a variety of human cancers (34) , including liver cancer and targeting c-Myc is considered as a novel approach to treat HCC (35) . Recent studies have shown that BRD4 is overexpressed in HCC tissues and it promotes tumor growth and epithelial mesenchymal transition in HCC (36, 37) . Recent studies have shown that JQ1 reduced HCC cell growth by supressing BRD4 using MYC dependent or independent pathway (37, 38) . Focusing on the novel dual inhibitory activity of SF1126 towards PI-3K and BRD4, the aim of this study was to evaluate the anti-proliferative effect of SF1126 and Sorafenib as single agents and in combination and evaluate their effects on the PI3K/AKT/mTOR, Ras/Raf/MAPK and Myc signaling pathways in preparation for a Phase II trial in HCC.
Materials and Methods
Tissue culture, cell lines and reagents The human HCC cell lines, Hep 3B, Hep G2, SK-Hep1 were obtained from ATCC.
Huh7 cell line was obtained from Japanese Collection of Research Bio resources. All cell lines were authenticated by short tandem repeat DNA profiling at the respective cell banks and were maintained as recommended by the suppliers. These cells were cultured in DMEM medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum, 2 mM glutamine and 1% penicillin-streptomycin at 37ºC in a 5% CO 2 CA) on an CFX96 Real time system (Bio-Rad, Hercules, CA). cDNAs were amplified using specific c-Myc primers and primer sequences will be available upon request.
Chromatin immunoprecipitation (ChIP) studies
Huh7 and SK-Hep1 cells were treated with SF1126 (10 μM), JQ1 (1 μM), or vehicle control for 24 hours. Cells were then harvested for ChIP assay as previously reported (32) and described in Supplementary methods. ChIP and input DNA were analyzed by real-time PCR analysis as described before (24) To test the effect of SF1126 on HCC cell proliferation, we chose 4 different established HCC cell lines, Hep 3B, Hep G2, SK-Hep1 and Huh7. SF1126 as a single agent inhibited proliferation of all the cell lines tested (Fig. 1) . The IC 50 of SF1126 for Hep 3B, Hep G2, SK-Hep1 and Huh7 cells was found to be 5.05 µM, 6.89 µM, 3.14 µM and 2.14 µM respectively (Fig. 1A-D) . Importantly, these IC 50 concentrations are well within the pharmacokinetic levels of SF1126 achieved in the human Phase I trial (26) . Next, we evaluated the potency of the combination of SF1126 and Sorafenib in HCC proliferation. All four cell lines were treated with different concentrations of SF1126 and Sorafenib. The combination of SF1126 and Sorafenib resulted in an increased inhibition of HCC proliferation (Fig. 1) . As expected, differences were noted in the sensitivity for each cell line for each single agent and combination treatment. For Hep3B cells, IC 50 for Sorafenib and combination of SF1126 and Sorafenib was found to be 6.52 µM and 2.74 µM respectively (Fig. 1A) . For Hep G2 cells, IC 50 for Sorafenib and combination of drugs was found to be 8.6 µM, and 1.79 µM respectively (Fig. 1B) . For SK-Hep1 cells, IC 50 for Sorafenib and combination of SF1126 and Sorafenib was found to be 7.6 µM, and 0.52 µM respectively (Fig. 1C) . For Huh 7 cells, IC 50 s are 8.08 µM, and 0.65 µM for Sorafenib alone or in combination with SF1126 respectively (Fig. 1D) . Analysis of the enhanced cytotoxic effect in combination versus SF1126 or Sorafenib alone was performed using the Chou-Talalay method for calculating the combination index (CI), with values <1 suggesting synergism.
Combination of SF1126 and Sorafenib in Hep G2, SKHep-1 and Huh7cells resulted in CI values of 0.6, 0.7 and 0.5 which is consistent with synergistic inhibition of proliferation. For Hep 3B. The CI value is 1.049 suggests an additive effect of the drug combination (Supplementary Table S1 ). 
Combination of SF1126 and Sorafenib inhibits multiple key enzymes in PI-3K/AKT/mTOR and Ras/Raf/MAPK signaling pathways SF1126 as a single agent is known to inhibit PI3K/AKT/mTOR pathway in various cell lines (23, 27, 42) . SF1126 at 1 μM and 10 μM conc. significantly suppressed phosphorylation of AKT, p70S6K, and 4EBP1 in Hep 3B, Hep G2, SK-Hep1 and Huh7 cells in a dose dependent manner as determined by Western blot analysis (Fig. 3) . SF1126 supressed phosphorylation of ERK in Hep3B and Huh 7 cells while there is no effect or mild effect of this drug on pERK levels in SK-Hep1 and HepG2 cells respectively (Fig. 3) . As expected, Sorafenib showed no effect on phosphorylation of AKT, p70S6K and 4EBP1 in HepG2, SK-Hep1 and Huh7 cells (Fig. 3 B-D) . Interestingly, Sorafenib increased PI-3K signaling in Hep 3B cells (Fig. 3A) . Similar to this result, previous report has demonstrated that blockage/inhibition of only one of the main pathways PI3K/AKT/mTOR or Ras/Raf/MAPK, separately, can result in activation of the other pathway (16) . We next tested if Sorafenib alone or in combination with SF1126 can block the key enzymes of PI3K/AKT/mTOR and Ras/Raf/MAPK pathway. As shown in Fig. 3 , treatment of cells with combination of SF1126 and Sorafenib at 0.5 μM and 2.5 μM suppress phosphorylation of AKT, p70S6K, 4EBP1 and ERK in all the cell lines. These results suggest that combined treatment of SF1126 and Sorafenib blocked multiple key enzymes in PI3K/AKT/mTOR and Ras/Raf/MAPK pathway (Fig. 3) . This is correlated with greater antitumor activity in vivo.
The active moiety of SF1126, LY294002 binds to the active site of in BRD4 (BD1), inhibits BRD4 binding to acetyl lysine of H4 chromatin mark protein and displaces BRD4 from the MYC transcriptional start site in HCC.
Herein, we investigated the molecular interaction between LY294002, the active moiety of SF1126, and the BRD4 bromodomain binding domain 1 (BD1) (28) (Fig. 3) . It was previously shown that BET bromodomain inhibitors displace BRD4 from the MYC transcriptional start site, so we next investigated if SF1126 is able to displace BRD4 from the MYC promoter. Using chromatin immunoprecipitation (ChIP) with a BRD4 antibody followed by quantitative real-time PCR with primers designed against the MYC transcriptional start site, we observed marked BRD4 localization to the MYC transcriptional start site (>10-fold enrichment in comparison to a non-specific locus upstream of MYC and >100-fold enrichment in comparison to a non-specific control antibody). This BRD4 binding to the MYC transcriptional start site was significantly abrogated by treatment with SF1126 by 10-fold in comparison to a non-specific locus upstream of MYC and by 45-fold in comparison to a non-specific control antibody (Fig. 4 F & G) . The BRD4 inhibitor JQ1 was used as a positive control with similar efficacy. These results demonstrate that SF1126 is a dual PI-3K/BRD4 inhibitor that targets multiple signaling nodes dysregulated in HCC. 
Discussion
The present study was focused on the effect of SF1126 alone or in combination with Sorafenib in preclinical HCC models. We evaluated HCC proliferation, cell cycle, apoptosis, phosphorylation of the key enzymes in the PI-3K/mTOR/Ras/Raf pathways and anti-tumor activity in vivo. The conceptual framework for the investigation SF1126 alone or in combination with Sorafenib in HCC emerged from the literature in that: 1) PI-3K pathway is known to be activated in 30-50% of HCC cases (14) proliferation. In addition, the results of cell cycle analysis and apoptosis assays showed that G1 arrest and apoptosis were induced by SF1126 treatment alone and these effects were augmented in combination with Sorafenib. These results suggest that the antiproliferative effects of these agents is due to G1 arrest and apoptosis in the HCC cell lines and that the combination increased G1 arrest and apoptosis in vitro.
Western blot experiments demonstrated potent inhibition of key enzymes of both Ras/Raf/MAPK and PI3K/AKT/mTOR pathways when cells were treated with SF1126 and Sorafenib. SF1126 monotherapy strongly inhibited phosphorylation of S6K, 4EBP1 and AKT (Ser473). Sorafenib, as single agent, inhibited ERK phosphorylation, but interestingly it stimulated AKT (Ser473) phosphorylation. These results confirm the previous findings that inhibition of one of the canonical pathways may cause stimulation of the pathway in HCC cells (15, 16 Table:   Table 1 shown as mean ± SEM, *P <0.05, **P <0.01 and ***P <0.001 vs. vehicle, t test. analysis. Data in A and C is shown as mean ± SEM, *P <0.05, **P <0.01 and ***P <0.001 vs.
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vehicle control, t test. 
